Background Immune checkpoint inhibitors (ICIs) are effective for many cancers but often cause immune-related adverse events, particularly gastrointestinal (GI) complications such as colitis. Identifying risk factors for ICI colitis (CIC) could improve patient selection and discover potential mechanisms relevant to idiopathic inflammatory bowel disease (IBD). Prior studies on ICI risk factors have methodological limitations. Methods We used electronic health record…
Risk factors for immune checkpoint inhibitor colitis: a retrospective multi-center cohort study using electronic health records
medRxiv Oncology | | Chu, D. H. T., Schalkamp, A.-K., Rudrapatna, V. A.
Topics: immunotherapy, prevention, research